Alnylam Pharmaceuticals, Inc. (ALNY)
298.12
+5.96
(+2.04%)
USD |
NASDAQ |
Jun 09, 15:15
Alnylam Pharmaceuticals Research and Development Expense (Quarterly) : 364.87M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 210.17M |
| Incyte Corp. | 515.90M |
| BioMarin Pharmaceutical, Inc. | 178.80M |
| BridgeBio Pharma, Inc. | 126.64M |
| Insmed, Inc. | 209.48M |